In a report released yesterday, Neil Chatterji from B.Riley Financial maintained a Buy rating on Hyperfine (HYPR – Research Report), with a price target of $2.50. The company’s shares closed yesterday at $1.55.
Chatterji covers the Healthcare sector, focusing on stocks such as ClearPoint Neuro, Viewray, and Hyperfine. According to TipRanks, Chatterji has an average return of -5.9% and a 22.73% success rate on recommended stocks.
Currently, the analyst consensus on Hyperfine is a Moderate Buy with an average price target of $2.75.
See the top stocks recommended by analysts >>
HYPR market cap is currently $98.95M and has a P/E ratio of -1.14.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthCor Catalio Acquisition Corp is a blank check company.
Read More on HYPR:
- Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results
- Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results on March 21, 2023
- Hyperfine, Inc. Receives FDA Clearance for Updated Software to Further Improve Diffusion-Weighted Imaging
- Hyperfine receives FDA 510(k) clearance for Swoop system software update
- Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations
